Adherium's Smart Solution for Respiratory Health – A Game Changer?

In this video, Unknown Host chats with Dawn Bitz, the CEO of Adherium (ADR.ASX), about how their innovative smart jackets are transforming the management of respiratory health. With over 60,000 patients in their insurance-verified funnel, Adherium is leveraging technology to enhance medication adherence and reduce hospitalisations. Dawn shares insights on the company's impressive growth plans, including targeting 10,000 remote patient monitoring (RPM) patients by 2026 through partnerships in the healthcare sector. We discuss Adherium's partnership with the prestigious Intermountain Health system and the groundbreaking data that could redefine adherence metrics and patient outcomes. We also delve into plans for future value-based contracts within the US insurance market. Timestamps: 00:00 - Introduction to Adherium and Dawn Bitz 00:30 - Overview of Adherium’s smart-jacket technology 03:00 - Importance of medication adherence in respiratory health 05:00 - Dawn’s experience meeting with investors 08:00 - RPM revenue model and projections 11:00 - Future plans for scaling RPM and partnerships with Insurers 14:00 - How Adherium is ensuring sustainable growth If you enjoy this content and want to stay updated on Adherium’s developments, make sure to hit that subscribe button and turn on notifications! ⚠️ IMPORTANT DISCLAIMER: This content is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consider seeking advice from a qualified financial advisor before making investment decisions. The creator may hold positions in securities discussed. 📌 Articles: https://smallcaps.com.au/australian-market-follows-wall-street-down-market-wrap https://smallcaps.com.au/adherium-partners-astrazeneca-hailie-smartinhaler-clinical-trial https://smallcaps.com.au/adherium-hailie-smartinhaler-fda-approval-astrazeneca-devices https://smallcaps.com.au/adherium-us-health-group-remote-medical-management-high-risk-respiratory-patients https://smallcaps.com.au/adherium-receives-fda-grant-market-smartinhaler-us 🔎 More on Adherium: https://smallcaps.com.au/stocks/asx-adr/ ⸻ Small Caps is Australia’s #1 site for market news & information on ASX-listed small cap companies. 🌐 WEBSITE https://smallcaps.com.au/ 🎧 PODCAST https://smallcaps.com.au/podcast/ 📱 SOCIAL MEDIA Facebook: https://www.facebook.com/SmallCapsASX Twitter: https://twitter.com/SmallCapsASX LinkedIn: https://www.linkedin.com/company/small-caps/ 📬 NEWSLETTER https://smallcaps.com.au/subscribe/